AU2022386489A1 - Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof - Google Patents

Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof Download PDF

Info

Publication number
AU2022386489A1
AU2022386489A1 AU2022386489A AU2022386489A AU2022386489A1 AU 2022386489 A1 AU2022386489 A1 AU 2022386489A1 AU 2022386489 A AU2022386489 A AU 2022386489A AU 2022386489 A AU2022386489 A AU 2022386489A AU 2022386489 A1 AU2022386489 A1 AU 2022386489A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
oeg
ala
ile
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022386489A
Other languages
English (en)
Inventor
Xueteng CAO
Jing Chen
Zhenbin Li
Kai Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Pharmaceutical Co Ltd
Publication of AU2022386489A1 publication Critical patent/AU2022386489A1/en
Assigned to JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. reassignment JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. Request for Assignment Assignors: Fujian Shengdi Pharmaceutical Co., Ltd., JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2022386489A 2021-11-12 2022-11-11 Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof Pending AU2022386489A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111341752 2021-11-12
CN202111341752.0 2021-11-12
PCT/CN2022/131375 WO2023083301A1 (zh) 2021-11-12 2022-11-11 Glp-1受体和gip受体双重激动剂的药物组合物及其用途

Publications (1)

Publication Number Publication Date
AU2022386489A1 true AU2022386489A1 (en) 2024-05-23

Family

ID=86335124

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022386489A Pending AU2022386489A1 (en) 2021-11-12 2022-11-11 Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof

Country Status (10)

Country Link
US (1) US20250115654A1 (https=)
EP (1) EP4431522A4 (https=)
JP (1) JP2024546026A (https=)
KR (1) KR20240109258A (https=)
CN (1) CN118103391A (https=)
AU (1) AU2022386489A1 (https=)
CA (1) CA3237796A1 (https=)
MX (1) MX2024005663A (https=)
TW (1) TW202333773A (https=)
WO (1) WO2023083301A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116693652B (zh) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用
TW202529797A (zh) * 2023-12-12 2025-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途
WO2025149039A1 (zh) * 2024-01-12 2025-07-17 杭州中美华东制药有限公司 长效glp-1/gip双激动剂的药物组合物
WO2025252197A1 (zh) * 2024-06-07 2025-12-11 江苏恒瑞医药股份有限公司 药物组合物
WO2026037397A1 (zh) * 2024-08-16 2026-02-19 江苏恒瑞医药股份有限公司 Glp-1类似物的医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
WO2012088379A2 (en) * 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
US9453062B2 (en) * 2011-06-10 2016-09-27 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
IN2014MN02304A (https=) * 2012-05-03 2015-08-07 Zealand Pharma As
AU2013366692B2 (en) * 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
EP3642238A1 (en) * 2017-06-21 2020-04-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
SG11202103137WA (en) * 2018-10-26 2021-04-29 Novo Nordisk As Stable semaglutide compositions and uses thereof
CN112351994B (zh) * 2019-04-11 2024-06-07 江苏豪森药业集团有限公司 一种多受体激动剂及其医药用途
US20220372072A1 (en) * 2019-09-19 2022-11-24 Dr. Reddy's Laboratories Limited Improved purification processes for liraglutide
EP4086277A4 (en) * 2019-12-30 2024-02-14 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting glp-1 compound
CN114222755B (zh) * 2020-05-29 2024-06-11 北京拓界生物医药科技有限公司 Glp-1和gip受体双重激动剂化合物及其应用

Also Published As

Publication number Publication date
MX2024005663A (es) 2024-05-28
JP2024546026A (ja) 2024-12-17
EP4431522A1 (en) 2024-09-18
EP4431522A4 (en) 2025-03-26
KR20240109258A (ko) 2024-07-10
CA3237796A1 (en) 2023-05-19
US20250115654A1 (en) 2025-04-10
TW202333773A (zh) 2023-09-01
WO2023083301A1 (zh) 2023-05-19
CN118103391A (zh) 2024-05-28

Similar Documents

Publication Publication Date Title
US20230190879A1 (en) Dual-agonist compound for both glp-1 and gip receptors and application thereof
US20250115654A1 (en) Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
AU2020256648B2 (en) Multi-receptor agonist and medical use thereof
US8501693B2 (en) Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
US20090209469A1 (en) Use of Exendins and GLP-1 Receptor Agonists for Altering Lipoprotein Particle Size and Subclass Composition
CN113383014A (zh) 双受体重激动剂化合物及其药物组合物
US20260014232A1 (en) Pharmaceutical Composition of GLP-1 and GIP Receptor Dual Agonist and Use Thereof
US11931417B2 (en) Methods of preparing a pegylated human IL-11 composition
TW202502808A (zh) Glp-1、gip和gcg受體三激動劑及其應用
EA053272B1 (ru) Фармацевтическая композиция двойного агониста рецептора glp-1 и рецептора gip и ее применение
RU2848325C1 (ru) Соединение с двойной агонистической активностью в отношении рецепторов glp-1 и gip и его применение
RU2816492C2 (ru) Мультирецепторный агонист и его медицинское применение
HK40069563B (zh) Glp-1和gip受体双重激动剂化合物及其应用
HK40069563A (en) Dual-agonist compound for both glp-1 and gip receptors and application thereof
HK40051504A (en) Dual receptor-acting agonist compounds and pharmaceutical composition thereof
AU2026202757A1 (en) Multi-receptor agonist and medical use thereof
TW202545982A (zh) 胰島澱粉樣多肽類似物及其醫藥用途
HK40043112A (en) Multi-receptor agonist and medical use thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

Free format text: FORMER APPLICANT(S): FUJIAN SHENGDI PHARMACEUTICAL CO., LTD.; JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.